Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Calcium timing during bypass may cut need for heart drugs

NCT ID NCT03772990

Disease control Sponsor: Meshalkin Research Institute of Pathology of Circulation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 30, 2026 · Last updated Aug 05, 2026 · Updated 3 times

Summary

This trial tests whether giving calcium chloride as patients come off cardiopulmonary bypass reduces the need for drugs that support the heart and blood pressure. About 800 adults having valve or combined valve-and-bypass surgery will receive either calcium or a placebo. The goal is to see if a simple calcium dose can stabilize the heart during this critical transition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
calcium chloride
What this could lead to
If giving calcium at the right time reduces the need for strong heart medications after bypass, it could make cardiac surgery safer and recovery smoother.
What could go wrong
This is a single-center trial, and calcium can also cause dangerous side effects like heart rhythm problems or coronary spasm if levels get too high.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

820 people

The number who actually took part.

Started

Jan 2019

Finished

Aug 2025

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * surgery under cardiopulmonary bypass * valve or valve surgery + CABG * age \> 18 years * signed informed consent Exclusion Criteria: * emergency surgery * isolated aortic valve repair/replacement * isolated CABG * planned (before surgery) blood transfusion * redo surgery * known allergy to the study drug * pregnancy * current enrollment into another RCT (in the last 30 days) * previous enrollment and randomization to ICARUS trial - liver cirrhosis (Child B or C) * transfusion during CPB * hypo- or hyperparathyreosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiac surgery are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiac surgery Cardiopulmonary bypass

Contacts and locations

Locations

  • B.V. Petrovsky Russian Scientific Surgery Center

    Moscow, Russia

  • District clinical hospital

    Khanty-Mansiysk, Russia

  • Federal Center for Cardiovascular Surgery

    Astrakhan, Russia

  • Federal Center for Cardiovascular Surgery

    Chelyabinsk, Russia

  • Federal Center for Cardiovascular Surgery

    Penza, Russia

  • King Abdullah Medical City

    Mecca, Saudi Arabia

  • M. Vladimirsky Moscow Regional Research Cinical Institute (MONIKI)

    Moscow, Russia

  • Meshalkin Research Institute of Pathology of Circulation

    Novosibirsk, 630055, Russia

  • Sh. Mohammed Bin Khalifa Bin Salman Al-Khalifa Cardiac Center

    Manama, Bahrain

  • St Petersburg University Multifunctional Clinical Centre

    Saint Petersburg, Russia

  • Tomsk National Research Medical Center

    Tomsk, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.